世界血友病連盟（WFH）は、世界の出血性疾患コミュニティを招集し、現行の、あるいは新規の治療や医療を受ける機会の公平性を確保することで、世界的権利擁護支援活動の指導的役割を果たしています。また、世界や地域の権利擁護活動を生かして、政策、医療提供、必需品の調達に関連する各国の支援戦略を強化しています。
2025年までの5年間の構想として導入された新たなWFH医療と治療へのアクセス供与（ Path to Access to Care and Treatment：PACT）プログラムは、支援と診断を向上させ、遺伝性出血性疾患患者が持続可能なケアを受けられる機会を増やすようデザインされています。これは、トレーニング、教育、パートナーシップ、国内での取り組み、そしてエビデンスに基づく権利擁護支援活動によって達成可能となります。
出血性疾患コミュニティに属する患者に適切なケアを受ける機会を提供するにあたり、世界中の多くの国々が多くの課題に直面しています。実際に診断された血友病患者数と想定される患者数の差は、これまでに考えられていたものよりも大きく、現時点までに世界で血友病と確認された患者数は、想定される数字の3分の1にすぎません。PACTは、患者の全体像を把握するというニーズに応えることで、世界の出血性疾患コミュニティを支援することを目的としています。
PACTプログラムが目指すところは以下のとおりです。
このプログラムは、以下の3つの主な項目により実施されます。
PACT支援アカデミー（PACT Advocacy Academy）は、ケアの基本的概念と原理、治療や必要物品へのアクセス、医療経済学の概説、権利擁護支援プログラムの立案と実施など、エビデンスに基づく権利擁護支援キャンペーンを滞りなく実行するために必要な知識やスキルを、NMOのリーダーや患者支援者に提供します。
医療従事者に対しては、支援、診断、出血性疾患の管理に重点を置いたバーチャルトレーニングを年1回実施します。トレーニングの成果を継続的に評価し、新たなニーズや進捗度を判定します。
4、5年計画での個々のアクセスプランには、個別トレーニング、支援や権利擁護のキャンペーンに向けた現場サポートが含まれており、政府からの国家的支援を引き出します。これらのプログラムを最大限に成功させるために、主要な利害関係者（NMO、医療従事者、各国政府）の協力関係が育成されます。
対象となる国のNMOへの特定分野の専門家によるメンターシップ（指導体制）は、国のアクセスプランの実施を後押しします。このメンターシップ期間は、現地のニーズにより6カ月から4年となります。
WFHは、対象となる国のNMOに対して、WFH PACTプログラムの指導者となり、国のアクセスプランの実施を支援する特定分野の専門家ボランティアを募集しています。
メンターシップの主な目的は、以下に示すテーマや組織力の分野において、NMOにガイダンスや専門知識を提供し、PACTによる国のアクセスプランの効果を最大限にすることです。
指導期間は6カ月から4年間で、現地のニーズや指導者の都合により個別に設定されます。
WFHは、以下のうち少なくとも1つの分野において豊富な経験と専門知識を持つ指導者を求めています
国家的な出血性疾患プログラムと医療提供
擁護支援と政府支援
NMOの組織力とリーダーシップ
NMOの支援、教育プログラムおよびサービス
PACTプログラムに指導者として参加申請した方は全員、確認書を受け取り、指導者候補のデータベースに追加されます。次いで、指導者の専門およびPACTプログラムの一環として現在実施されている国家プロジェクトのニーズを考慮し、マッチングが行われます。マッチングされると、指導者に確認の連絡をします。
次に、WFHのスタッフが指導者とNMOとの顔合わせの会合を主催し、メンターシップの目的や範囲について検討するとともに、両者の協力の意志を固めます。メンターシップが始まると、指導者とNMOはWFHに対し進捗状況を定期的に報告します。
以下は、指導者がNMOに対して行う支援の一例です。
上記の領域での経験や専門知識をお持ちの方は、指導者応募用紙にご記入いただき、履歴書とともに [email protected] にお送りください。
世界や地域のトレーニングおよび会議（2022年開始）は、エビデンスに基づく権利擁護支援に関する成功事例と経験をコミュニティのリーダー間で共有するためのフォーラムとして機能します。こういった共同フォーラムでは、NMOリーダー、医療従事者、政府代表者が一堂に会し、利害関係者間の対話を進め、参画を増やします。
PACTのオンライン・トレーニングや教育、世界・地域会議の内容は、どの国からも閲覧することができますが、国のアクセスプランの作成や実施については20カ国が選定されています。この国々は、以下の基準により選定されています。
PACTには、以下の国々が登録されています。アルゼンチン、バングラデシュ、ボリビア、ブラジル、中国、コスタリカ、エジプト、インド、インドネシア、ケニア、マレーシア、メキシコ、ネパール、ニカラグア、ナイジェリア、パキスタン、パレスチナ、セネガル、ベトナム、ザンビア。
PACT支援アカデミーは、エビデンスに基づく権利擁護支援キャンペーンを成功させるために必要な知識やスキルを、NMOリーダーや患者支援者、医療従事者（HCP）に提供します。8カ月のコースには以下のトピックが含まれています。
PACT支援アカデミーは毎年開催され、第一期の開始は2022年1月です。初年度のPACT支援アカデミーのコースは英語で実施され、世界各国から20〜30名の参加を予定しています。今後は、英語以外の言語による実施も検討中です。
このコースは、WFH、ニューヨーク大学ロバートFワーグナー公共事業大学院（New York University Robert F. Wagner Graduate School of Public Service：NYU Wagner）および専門家ワーキンググループの協力で開設されています。
各トピックを6〜8週間にわたり学習する予定で、これには1つの自習用オンライン学習モジュールおよび2つのライブ形式の双方向ウェビナーが含まれています。オンラインプラットフォームにより、参加者は進捗状況の確認、過去のモジュールの参照、他の参加者や指導者との意見交換が可能です。
コース開催期間中、参加者は自身が所属するNMO向けに実際に権利擁護支援プロジェクトを開始する必要があります。PACT諸国からの参加者の場合、このプロジェクトはPACTによる国のアクセスプランと整合していなければなりません。
参加者には、WFHとNYU Wagnerから修了証が授与されます。
PACT支援アカデミーの参加者は、毎年公募により選定されます。2023年期の選考手続きは、すでに終了しています。2023年9月に募集を再開する予定です。
PACTプログラムについてご質問がある場合には、WFH（[email protected]）にお問い合わせください。
WFHデータ収集プログラムを介して収集されたデータを利用して、世界中のケアの格差を明らかにし、NMOおよび医療従事者（HCP）が使用可能なグラフ、チャート、インフォグラフィック、ツールを作成し、権利擁護支援メッセージを強化します。
インフォグラフィックは、最新の年次グローバル調査（AGS）および世界出血性疾患レジストリ（WBDR）のデータに基づいて作成されており、画像、PDFまたはスライドとしてダウンロードしたり、プレゼンテーションや権利擁護支援活動に利用したりすることができます。
WFHは、リアルタイムでカスタマイズ可能なクエリを含む、使いやすいデータ可視化システムを開発しました。このシステムによりユーザーは、報告、研究、権利擁護支援のあらゆるニーズに合わせて、最新のデータと過去のデータを検索・比較することができます。
WFHの新しいデータ収集システムを使用して作成されたAGSデータのグラフを閲覧・ダウンロードする。
WFH AGSミニレポートは、AGSデータのさらに詳細な展望や背景情報が得られる支援ツールです
血友病および他の出血性疾患に関連するグローバルデータ、および患者登録に関する査読付き論文も利用可能です。
WFH遺伝子治療円卓会議（Gene Therapy Round Table：GTRT）は、NMO、患者支援者、HCP、規制当局や業界代表者が一堂に会し、血友病の遺伝子治療に関連して現段階の世界的開発状況や予想される課題を共有するものです。
WFH遺伝子治療円卓会議（Gene Therapy Round Table：GTRT）は、招待制の会議です。主な科学専門家、規制当局、支払人、患者リーダーや患者支援者、HCP、科学者、業界代表者など、国際的な出血性疾患コミュニティから毎年80名ほどが招待されます。
この円卓会議は、世界中の血友病患者（PWH）に対する遺伝子治療開発に関連する課題の理解を深めることを目的としています。主要な課題や議論は、世界的に見る遺伝子治療へのアクセス機会、規制や財政上の課題、遺伝子治療の不明な部分、安全性および有効性の長期追跡調査が中心となっています。また、複数の利害関係者およびグローバルな視点も考慮されています。WFH GTRTからの報告が公開されています。
Keep up to date on the latest developments in the bleeding disorders community, from medical advances to important events.
© 2023 World Federation of Hemophilia
Charitable Registration No: 108222050 RR 0001
Advocacy
Humanitarian Aid
Identification and diagnosis
Treatment and care
Research and data collection
Training
Education & eLearning
The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.
Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.
References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.
The WFH does not collect personally identifying information about you when you visit our site, unless you choose to provide such information to us. Providing such information is strictly voluntary. This policy is your guide to how we will handle information we learn about you from your visit to our website.
Throughout our website, we provide links to other servers which may contain information of interest to our readers. We take no responsibility for, and exercise no control over, the organizations, views, or accuracy of the information contained on other servers. When linking to the WFH, we request that you ensure that there are no associated connections for commercial purposes. Any official use of the name WFH or the use of its logo needs to be approved by the WFH. If you have a link you’d like us to consider adding to our website, please send an email to [email protected] with the subject “Link request.”
All information, photographs, graphics, and other material on this website are protected by copyright. While users of this website may use the content for personal, non-commercial use, none of the content of this website can be modified, translated, transferred or sold, copied, reproduced, published, or distributed, in whole or in part, without the prior written consent of the WFH. To view a copy of the WFH’s permissions guidelines, click here.
The WFH encourages the dissemination of its information and welcomes proposals on the reprinting, redistribution, and translation of its materials. If you would like to publish information that you find on our website, please send your request to [email protected].
If you have suggestions on how to make the site more accessible, please contact us at [email protected].
Our website provides users the opportunity to opt-out of receiving communications from us through a special online form or via the communication they have received. You may, at all times, choose to receive which communications within the organization you can receive or none at all. You may also update your contact information previously provided to us via another online form.
If you have any questions about this privacy statement, the practices of this site, or your dealings with this website, you can contact us at [email protected].
The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.
If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).
We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.
Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Malmö Centre for Thrombosis and Haemostasis
Department for Hematology and Coagulation Disorders, Skåne University Hospital
Skåne University Hospital
Hospital Universitario La Paz
Haemostasis and Thrombosis Unit
Haematology Service, University and Polytechnic Hospital
Haemophilia Comprehensive Care Centre
Charlotte Maxeke Johannesburg Academic Hospital
Singapore General Hospital Haemophilia Treatment Clinic
Centre International de Traitement de l’Hémophilie (CITH) de Dakar
Centre National de Transfusion Sanguin (CNTS)
National Medical Research Center of Hematology of the Russian Academy of Medical Sciences
Van Creveldkliniek
University Medical Centre Utrecht
Nara Hemophilia Centre
Nara Medical University
National Hemophilia Center, Tel Hashomer
Sheba Medical Center
Katharine Dormandy Haemophilia Centre and Thrombosis Unit
Royal Free Hospital
Manchester Haemophilia Comprehensive Care Centre (Children’s and Adult’s)
Manchester Royal Infirmary and Manchester Children’s Hospital
Oxford Haemophilia Centre and Thrombosis Centre
Churchill Hospital
Sheffield Haemophilia and Thrombosis Centre
Royal Hallamshire Hospital
National Institute of Immunohaematology (ICMR) and KEM Hospital
Christian Medical College, Vellore
Paris Haemophilia Centre (Necker (N) and Kremlin Bicetre (KB) Hospitals)
Shabrawishi Hospital, Egyptian Society of Hemophilia, and Cairo University
University of Toronto Hemophilia Centres
St. Michael’s Hospital
Hemocentro – “Unidade de Hemofilia Cláudio Luiz Pizzigatti Corrêa”
Hemocentro Unicamp, University of Campinas
Haemostasis and Thrombosis Unit
Division of Haematology
Cliniques universitaires Saint-Luc
Hemofiliecentrum Leuven, University of Leuven
Medical University of Vienna
Department of Medicine I
Clinical Division of Hematology and Hemostaseology
Ronald Sawers Haemophilia Centre
Instituto Asistencial “Dr. Alfredo Pavlovsky”
(Fundación de la Hemofilia)
Instituto De Investigaciones Hematológicas “Dr. Mariano R. Castex” (IIHEMA
(Academia Nacional de Medicina)
International Hemophilia Training Center – Bangkok
Ramathibodi Hospital
Mahidol University
University of North Carolina Hemophilia & Thrombosis Center
Nationwide Children’s Hospital
Gulf States Hemophilia and Thrombophilia Center
University of Texas Health Science Center at Houston
Orthopaedic Hemophilia Treatment Center
Mount Sinai School of Medicine
Mount Sinai Medical Center
Mayo (Rochester) Comprehensive Hemophilia Center, and International Hemophilia Training Center (WFH)
Mayo Clinic/Foundation and Mayo Medical School
Hemophilia & Thrombosis Treatment Center
University of California San Diego
| 2012 | Christine Lee United Kingdom |
| 2006 | Dr. Bruce Evatt United States |
Recognizing that training women leaders ensures the diversity our community need to thrive; the Hemophilia Alliance has been a longtime supporter of the Susan Skinner Memorial Fund. They deepened their engagement with the global community through the establishment of the Travel Grant Program, which allows US-based multidisciplinary healthcare professionals the opportunity to attend WFH global training workshops. The wealth of experience and perspective attendees bring back home to their communities helps patients across the country. Their patience and support as we grappled with changing norms in these challenging times gave us the flexibility to meet our community’s needs with revamped programming.
Hemophilia of Georgia has stood with us for over three decades, playing an early role in distributing donated factor via the WFH Humanitarian Aid program. Our relationship has deepened over the years as they continued to support this program and came on board as a founding Chapter Challenge champion in 2016. Their belief in educating future leaders is clear in their investment in the Youth Leadership Workshops, which has led to the training of over 50 young adults. They also support workshops devoted to educating providers and patient leaders on how to collect and use data to advocate for better patient care. Their staff generously volunteer their time as trainers and as well as serving on various committees.
The National Hemophilia Foundation helps advance our mission on several fronts. They inspire others to follow their lead as a founding champion of the NHF Chapter Challenge. Their commitment to equality of access is demonstrated in their support of the Cornerstone Initiative, which lays the foundation for care in the world's most underserved regions, as well as programs that aim to raise awareness and improve care of women with bleeding disorders and those with von Willebrand disease. We also benefit from their steadfast engagement with various programs including the WFH Twinning Program and their individual leaders’ contribution to our leadership and committees.
Do you sometimes wish you could do more? A bequest is a simple way for you to make a significant gift without changing anything about your financial security and lifestyle today. Your legacy will sustain care for the generations to come.
Download these sample clauses to give to your legal advisor.
We understand if you prefer to remain anonymous, but we would be very honoured if you would let us know of your intentions so that we may thank you personally. We would also be happy to answer any questions you may have or give you additional information. Please contact Jennifer Laliberté at 514‑875‑7944 ext.2822 or [email protected].
The information on the WFH USA website is provided for general information purposes only. The WFH USA does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH USA recommends that you contact your physician or local treatment centre. Before administering any products, the WFH USA urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
While every effort has been made to ensure the accuracy of the information on this site, the WFH USA does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.
Messages posted to WFH USA discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH USA social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH USA recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.
References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH USA. The WFH USA is not responsible and assumes no liability for the content of any linked websites.
The WFH USA does not collect personally identifying information about you when you visit our site, unless you choose to provide such information to us. Providing such information is strictly voluntary. This policy is your guide to how we will handle information we learn about you from your visit to our website.
Throughout our website, we provide links to other servers which may contain information of interest to our readers. We take no responsibility for, and exercise no control over, the organizations, views, or accuracy of the information contained on other servers. When linking to the WFH USA, we request that you ensure that there are no associated connections for commercial purposes. Any official use of the name WFH USA or the use of its logo needs to be approved by the WFH USA. If you have a link you’d like us to consider adding to our website, please send an email to [email protected] with the subject “Link request.”
All information, photographs, graphics, and other material on this website are protected by copyright. While users of this website may use the content for personal, non-commercial use, none of the content of this website can be modified, translated, transferred or sold, copied, reproduced, published, or distributed, in whole or in part, without the prior written consent of the WFH USA. To view a copy of the WFH USA’s permissions guidelines, click here.
The WFH USA encourages the dissemination of its information and welcomes proposals on the reprinting, redistribution, and translation of its materials. If you would like to publish information that you find on our website, please send your request to [email protected].
If you have suggestions on how to make the site more accessible, please contact us at [email protected].
Our website provides users the opportunity to opt-out of receiving communications from us through a special online form or via the communication they have received. You may, at all times, choose to receive which communications within the organization you can receive or none at all. You may also update your contact information previously provided to us via another online form.
If you have any questions about this privacy statement, the practices of this site, or your dealings with this website, you can contact us at [email protected].
The WFH USA has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH USA staff or falsely stating that they are associated with the WFH USA. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH USA, are fraudulent and come from outside of our organization.
If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH USA emails come from @wfhusa.org or @wfh.org).
We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH USA at [email protected] or call 1-877-417-7944.
The WBDR Minimal Data Set (MDS) is a set of data on demographics, diagnosis, symptoms and treatment which are collected on patients participating in the WBDR.
The WBDR Extended Data Set (EDS) is a larger set of data, with more details than the MDS, which includes questions on patient demographics, diagnosis, symptoms, treatment and burden of disease. The EDS can be used by hemophilia treatment centers to collect data on patients participating in the WBDR. The WBDR Extended Data Set (EDS), was added to the database in March 2019.
| 2012 | Piet de Kleijn The Netherlands |
| 2010 | Dr. Mammen Chandy India |
| 2008 | Dr. Man-Chiu Poon Canada |
| 2006 | Dr. Norma de Bosch Venezuela |
| 2004 | Dr. Parttraporn Insarangkura Thailand Dr. Carol K. Kasper United States |
| 2020 | Aluva (India) – Newcastle (UK) |
| 2019 | Yogyakarta / Solo (Indonesia) – Utrecht (Netherlands) |
| 2018 | Abidjan (Ivory Coast) – Brussels (Belgium) |
| 2017 | Santa Cruz de la Sierra (Bolivia) – Buenos Aires (Argentina) |
| 2016 | Kampala (Uganda) – London (UK) |
| 2015 | Varna (Bulgaria) – Bonn (Germany) |
| 2014 | Arequipa (Peru) – Los Angeles (USA) |
| 2013 | Davangere (India) – Liverpool (UK) Ludhiana (India) – Detroit (USA) |
| 2012 | Hanoi (Vietnam) – Melbourne (Australia) |
| 2011 | Manado (Indonesia) – Utrecht (Netherlands) |
| 2010 | Delhi (India) – Winnipeg (Canada) Yaoundé (Cameroon) – Geneva (Switzerland) |
| 2009 | Chisinau (Moldova) – Warsaw (Poland) Colombo (Sri Lanka) – Vellore (India) |
| 2008 | Gaborone (Botswana) – Philadelphia (USA) |
| 2007 | Vientiane (Laos) – Brest (France) Damascus (Syria) – Montpellier (France) |
| 2006 | Lima (Peru) – Fort Worth (USA) |
| 2005 | Yerevan (Armenia) – Minneapolis (USA) Casablanca (Morocco) – Caen (France) |
| 2004 | Beirut (Lebanon) – Geneva (Switzerland) Santo Domingo (Dominican Republic) – Caracas (Venezuela) |
| 2003 | Cairo (Egypt) – Knoxville (USA) |
| 2002 | Moscow (Russia) – Liverpool (UK) Panama – Valencia (Spain) |
| 2001 | Bangalore (India) – St. Louis (USA) |
| 2000 | Pune (India) – Bradford (UK) |
| 1999 | Montevideo (Uruguay) – Buenos Aires (Argentina) Tianjin (China) – Calgary (Canada) |
| 1998 | Plovdiv (Bulgaria) – Bonn (Germany) |
| 1997 | Bogota (Colombia) – Los Angeles (USA) Tartu (Estonia) – Stockholm (Sweden) |
| 1996 | Timisoara (Romania) – Munich (Germany) Riga (Latvia) – Munster (Germany) |
| 1995 | Klaipeda (Lithuania) – Malmo (Sweden) |
| 1994 | Bratislava (Slovakia) – Tel Hashomer (Israel) |
| 2021 | Axel Seuser Germany |
| 2019 | Dr. Adolfo Llinás Colombia |
| 2017 | Pamela Hilliard Canada |
| 2015 | Kathy Mulder Canada |
| 2013 | James Luck United States |
| 2012 | Piet de Kleijn The Netherlands |
| 2011 | Dr. Lily Heijnen The Netherlands |
| 2010 | Dr. Horacio Caviglia Argentina |
| 2009 | Jerome D. Wiedel United States |
| 2008 | Dr. Federico Fernández-Palazzi Venezuela |
| 2007 | Michael Heim Israel |
| 2006 | Brenda Buzzard United Kingdom |
| 2005 | Dr. Marvin Gilbert United States |
| 2021 | Baolai Hua Yangzhou College, Xuzhou Medical University |
The effects of intra-articular injection of TNF-alpha Antagonists in treatment of haemophilic synovitis |
| 2019 | Maarten Eerdekens Belgium |
Association between multi-segment foot kinetics and blood induced joint damage in adult patients with hemophilic ankle arthropathy |
| 2017 | Fabio Souza Brazil |
Decrease in joint inflammation, swelling and pain after a swimming protocol in animal model of experimental-induced hemarthrosis |
| 2015 | SM Javd Mortazavi Iran |
Bilateral total knee arthroplasty in patients with hemophilia: A safe and cost-effective procedure |
| 2013 | Lize F.D. van Vulpen United States |
A fusion protein of IL4 and IL10, is equally effective in protecting cartilage from blood-induced damage compared to the individual components |
| 2012 | Horacio Caviglia Argentina |
Pseudotumor Surgery in Haemophilia A patients: Comparitive results between inhibitor and non-inhibitor patients |
| 2011 | Nick Goddard United Kingdom and Monique van Meegeren The Netherlands |
Early onset administration of IL-4 and IL-10 prevents blood-induced cartilage damage in vitro |
| 2010 | Lydia Abad-Franch Spain |
Influence of an Aquatic Training Protocol on the Reduced Risk of Cardiovascular Morbidity and Mortality in a Hemophiliac |
| 2009 | Sebastien Lobet Belgium |
Impact of Hemophilia Ankle Arthropathy on Gait Disability: Analysis of Energetic and Mechanical Variables |
| 2008 | Jose Alberto Tlacuilo-Parra Mexico |
Bone Turnover Markers and Bone Mineral Density in Children with Hemophilia |
| 2007 | Natalie Jansen The Netherlands |
Protective Abilities of Interleukin-10 in Blood-induced Cartilage Damage |
| 2006 | Axel Seuser and E. Kusch Germany |
Multi-Center Study of Orthopedic Outcome of the Lower Extremities in 249 Children with Hemophilia |
| 2005 | Frank van Genderen, Nico van Meeteren, Lily Heijnen, Piet de Kleijn, Marijke van den Berg, Paul Helders The Netherlands |
The Hemophilia Activities List: Final development and validation of a hemophilic-specific self-assessment questionnaire on functional abilities |
| 2004 | Goris Roosendaal, Zalima N Jahangier, Kim MG Jacobs, Johannes WJ Bijlsma, Floris PJG Lafeber The Netherlands |
Radiosynoviorthesis using YTTRIUM-90 results in adverse direct effects on cartilage: a human in vitro study |
| 2003 | Axel Seuser, Thomas Wallny, Günter Schumpe, Elmar Trunz, Hans-Hermann Brackman Germany |
How to advise young haemophiliacs to find the right sport? A new and safe algorithm |
| 2002 | James Luck, Jr. and Mauricio Silva United States |
Long-Term Review of Total Knee Arthroplasty |
| 2001 | Federico Fernández-Palazzi Venezuela |
Oxytetracycline Chlorohydrate: A new material for chemical synovial orthoses |
| 2000 | Horacio Caviglia Argentina |
Pseudotumours |
| 1999 | William J. Ribbans and J.L. Hicks United Kingdom |
Communication and Co-operation for the New Millennium – The Future of the Musculoskeletal Committee in the 21st Century |
| 1998 | Adolfo Llinas, Mauricio Silva, Monica Duarte, Gonzalo Ucros, Graciela Perini, Angela Maria Cerquera, Andres Forero Colombia |
Chromic phosphate synoviorthesis without age restriction should be the first treatment option for chronic active hemophilic synovitis |
